Skip to content
  • Home
  • World News
  • Business
  • Aviation
195 news

195News

All the news that's fit to print

  • Home
  • World News
  • Business
  • Aviation
  • Toggle search form
  • Space Logistics Market is Projected to Grow Expeditiously: to Reach USD 19.8 Billion by 2040, Report
    Space Logistics Market is Projected to Grow Expeditiously: to Reach USD 19.8 Billion by 2040, Report Aviation
  • Massage Chairs for Business Announces Partnerships with Leading Brands for Enhanced Corporate Wellness
    Massage Chairs for Business Announces Partnerships with Leading Brands for Enhanced Corporate Wellness Business
  • Inspired by trip with Obama, Acclaimed Cuban-American architect releases book reclaiming once lost memories of Cuba
    Inspired by trip with Obama, Acclaimed Cuban-American architect releases book reclaiming once lost memories of Cuba World News
  • Day 465: war diaries w/Former Advisor to Ukraine President, Intel Officer  @arestovych  & #Feygin
    Day 465: war diaries w/Former Advisor to Ukraine President, Intel Officer @arestovych & #Feygin World News
  • COLLEGE HUNKS HAULING JUNK AND MOVING OPENS IN BURLINGTON, NEW JERSEY
    COLLEGE HUNKS HAULING JUNK AND MOVING OPENS IN BURLINGTON, NEW JERSEY World News
  • FAA Requires Aviation Organizations to Detect, Address Safety Risks Early
    FAA Requires Aviation Organizations to Detect, Address Safety Risks Early Aviation
  • Exec Capital launches International Team
    Exec Capital launches International Team Business
  • Countering the Wagner Group and Degrading Russia’s War Efforts in Ukraine
    Countering the Wagner Group and Degrading Russia’s War Efforts in Ukraine World News
GB Sciences’ First International Patent Protecting Its Proprietary Cannabinoid-Based Formulations for Parkinson’s Disease Has Been Issued in China

GB Sciences’ First International Patent Protecting Its Proprietary Cannabinoid-Based Formulations for Parkinson’s Disease Has Been Issued in China

Posted on March 20, 2023 By NewsEditor
GB Sciences’ First International Patent Protecting Its Proprietary Cannabinoid-Based Formulations for Parkinson’s Disease Has Been Issued in ChinaGB Sciences’ First International Patent Protecting Its Proprietary Cannabinoid-Based Formulations for Parkinson’s Disease Has Been Issued in ChinaAccording to Statista, China has the second largest pharmaceutical market in the world and plant-based medicines are very well accepted, which makes China a potential target market for Gb Sciences.

GB Sciences’ First International Patent Protecting Its Proprietary Cannabinoid-Based Formulations for Parkinson’s Disease Has Been Issued in China
Patent


LAS VEGAS, March 20, 2023 (Newswire.com) - Gb Sciences, Inc. (OTCQB:GBLX), a leading cannabis- and plant-inspired biopharmaceutical research and development company, has recently been issued a patent in China to protect its proprietary cannabinoid-containing formulation for the treatment of Parkinson's disease. China is an increasingly important pharmaceutical market with cultural acceptance of plant-based formulations, which is a good fit for Gb Sciences' drug candidates. Gb Sciences' first international patent also confirms that the Company's intellectual property strategy can work globally and strengthens the Company's patent portfolio. The global market for treatments of Parkinson's disease is projected to grow to $8.8 billion by the year 2026, and new therapies to address Parkinson's disease symptoms are greatly needed.

"The issuance of Gb Sciences' first international patent protecting methods of using our proprietary cannabinoid-containing formulations for treating Parkinson's disease is an important milestone in the development of these vitally important therapies. Gb Sciences' recent patent issued in China validates both our plant-inspired drug discovery process and intellectual property strategy, which involve defining and protecting Minimum Essential Mixtures," explained Dr. Andrea Small-Howard, President and Chief Science Officer of Gb Sciences, Inc. "Gb Sciences starts its drug discovery process with plant-based therapies that are working anecdotally or in traditional medical systems, then we systematically reduce the number of compounds to reveal Minimum Essential Mixtures. Gb Sciences' novel Minimum Essential Mixtures retain the increased efficacy of whole plant medicines, but they are easier to manufacture with precision at scale like single ingredient drugs. These Minimum Essential Mixtures are a viable alternative to standard single ingredient drugs or traditional whole plant medicines."

Gb Sciences' Minimum Essential Mixture-based drug development strategy does not aim to treat complex diseases as if they were caused by a single factor, but instead addresses the combination of factors that lead to a complex human disorder. Minimum Essential Mixtures (MEMs) are potentially more effective than single ingredient drugs because the different active ingredients target the multiple human processes responsible for complex diseases, such as neurodegeneration, heart disease, and cancers. As such, MEMs may offer a more holistic treatment for complex disorders such as Parkinson's disease that cannot be attributed to a single cause, while maintaining the manufacturing and quality control advantages of single ingredient drugs.

Gb Sciences' patent portfolio currently contains six issued U.S. and four issued foreign patents, as well as 15 U.S. and 49 foreign patent-pending applications that cover our novel AI-enabled drug discovery platform and proprietary plant-inspired therapies for more than 65 different disorders. 

To learn more about Gb Sciences, visit www.gbsciences.com.

About Gb Sciences and GbS Global Biopharma

Gb Sciences, Inc. is a plant-inspired, biopharmaceutical research and development company creating patented, disease-targeted formulations of cannabis- and other plant-inspired therapeutic mixtures for the prescription drug market through its Canadian subsidiary, GbS Global Biopharma, Inc. The 'plant-inspired' active ingredients in its therapeutic mixtures are synthetic homologues identical to the original plant compounds but produced under current Good Manufacturing Practices. Gb Sciences' intellectual property portfolio contains six issued U.S. and four issued foreign patents, as well as 15 U.S. and 49 foreign patent-pending applications. In its drug development pipeline, Gb Sciences has five preclinical phase product development programs. Gb Sciences' lead program for Parkinson's disease is being prepared for a first-in-human clinical trial. Gb Sciences' formulations for chronic pain, anxiety and depression are currently in preclinical animal studies with researchers at the National Research Council of Canada (NRC). The company also received positive preclinical proof-of-concept data supporting its complex mixtures for the treatment of Cytokine Release Syndrome, and its lead candidates will be optimized based on late-stage preclinical studies at Michigan State University. Gb Sciences' productive research and development network includes distinguished universities, hospitals, and Contract Research Organizations. To learn more, visit www.gbsciences.com.

Forward-Looking Statements

This press release may contain statements relating to future results or events, which are forward-looking statements. Words such as "expects," "intends," "plans," "may," "could," "should," "anticipates," "likely," "believes" and words of similar import may identify forward-looking statements. These statements are not historical facts, but instead represent only the Company's belief regarding future events, many of which, by their nature, are inherently uncertain and outside of the Company's control. It is possible that the Company's actual results and financial condition may differ, possibly materially, from the anticipated results and financial condition indicated in these forward-looking statements. Further, information concerning the Company and its business, including factors that potentially could materially affect the Company's business and financial and other results, are contained in the Company's filings with the Securities and Exchange Commission, available at www.sec.gov. All forward-looking statements included in this press release are made only as of the date of this press release, and we do not undertake any obligation to publicly update or correct any forward-looking statements to reflect events or circumstances that subsequently occur or of which we hereafter become aware.

Contact Information:
Alexis Quintal
[email protected]


Original Source: GB Sciences' First International Patent Protecting Its Proprietary Cannabinoid-Based Formulations for Parkinson's Disease Has Been Issued in China

The post GB Sciences’ First International Patent Protecting Its Proprietary Cannabinoid-Based Formulations for Parkinson’s Disease Has Been Issued in China first appeared on Social Gov.

Business

Post navigation

Previous Post: War Day 220: war diaries w/Advisor to Ukraine President, Intel Officer @arestovych & #Feygin
Next Post: War Day 219: war diaries w/Advisor to Ukraine President, Intel Officer @arestovych & #Feygin

Related Posts

  • Readout of Deputy Secretary Don Graves Meeting with Puerto Rico Financial Oversight and Management Board Executive Director Robert Mujica
    Readout of Deputy Secretary Don Graves Meeting with Puerto Rico Financial Oversight and Management Board Executive Director Robert Mujica Business
  • The Rising Star program by Natalia Ziajka is helping transform passion into a profitable business
    The Rising Star program by Natalia Ziajka is helping transform passion into a profitable business Business
  • Vendorland Chooses the Leading CRM Consulting Companies in May 2024
    Vendorland Chooses the Leading CRM Consulting Companies in May 2024 Business
  • 100 Black Men of America, Inc. Mourns the Loss of Beloved Chairman Thomas W. Dortch, Jr.
    100 Black Men of America, Inc. Mourns the Loss of Beloved Chairman Thomas W. Dortch, Jr. Business
  • Blow-Fill-Seal Technology Market Growth Analysis with Investment OpportunitiesFor 2024-2033
    Blow-Fill-Seal Technology Market Growth Analysis with Investment OpportunitiesFor 2024-2033 Business
  • Darian Braun Wins Another Beauty Award
    Darian Braun Wins Another Beauty Award Business
June 2025
M T W T F S S
 1
2345678
9101112131415
16171819202122
23242526272829
30  
« May    
last celebrity gossip
Gossip Stone - celebrity life and gossip

Recent Posts

  • Terradepth awarded 5-year contract in global offshore energyJune 4, 2025
  • Artem Mirolevich and Dmitry Trekhsvyatsky Launch Bold New ExhibitionJune 4, 2025
  • Global Data Systems Appoints Doug Pickle as President, Driving Strategic GrowthJune 4, 2025
  • Smith Earns ISO/IEC 17025 AS6171 Accreditation at Its Global Operational HubsJune 3, 2025
  • Trends, Growth, and Insights Through 2034June 3, 2025
Brand Values Content
VUGA Enterprises - media network PR & Marketing
  • Guy Colangelo Achieves Amazon Best-Seller Status with “Never Give Up,” Co-Authored with Dick Vitale
    Guy Colangelo Achieves Amazon Best-Seller Status with “Never Give Up,” Co-Authored with Dick Vitale Business
  • Kiln set to open 31,000-Square-Foot Boutique Coworking and Flexible Office Community at Riverside Downs in Littleton.
    Kiln set to open 31,000-Square-Foot Boutique Coworking and Flexible Office Community at Riverside Downs in Littleton. Business
  • Breaking Free from Trauma’ by Caitlin Emma Kirschenbaum
    Breaking Free from Trauma’ by Caitlin Emma Kirschenbaum World News
  • Upcoming Trends And Drivers Of The 3D Printed Wearables Market
    Upcoming Trends And Drivers Of The 3D Printed Wearables Market World News
  • How CBD Helped Save the Life of Stirling CBD’s Founder
    How CBD Helped Save the Life of Stirling CBD’s Founder Business
  • SARAH ZOHAR SELECTED AS TOP LEAD INTERIOR DESIGNER AND OWNER OF THE YEAR BY IAOTP
    SARAH ZOHAR SELECTED AS TOP LEAD INTERIOR DESIGNER AND OWNER OF THE YEAR BY IAOTP World News
  • Mvix Launches a Device-Agnostic, Visual Communication Platform for Hybrid Workforce and Remote Audience
    Mvix Launches a Device-Agnostic, Visual Communication Platform for Hybrid Workforce and Remote Audience Business
  • The Gaming Industry is under attack
    The Gaming Industry is under attack Business
aerospace company
stem cell clinic in kiev
medical spa in miami
Fashion TV free

Copyright © 2023 195 News. All Rights Reserved by Coolaser | Partner of VUGA Enterprises |  Advertising: Get Published

Powered by .